IP Library Granted Patent US 10,071,958
Granted Patent B2
US 10,071,958 · App. 14/888,576 · Granted Sep 11, 2018

Method for producing alpha-substituted cysteine or salt thereof or synthetic intermediate of alpha-substituted cysteine

Inventors: Yuuki Asuma (Kanagawa, JP); Hisatoshi Uehara (Kanagawa, JP); Tomoko Maeda (Kanagawa, JP); Yasuyo Saito (Kanagawa, JP); Ryoma Miyake (Kanagawa, JP); Hiroshi Kawabata (Kanagawa, JP)
Assignee: API Corporation
C07C319/06C07C319/02C07C319/14C07C319/20C07C323/52C07C323/58C07C323/60C07D277/14C12P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,958
App. No.
14/888,576
Granted
Sep 11, 2018
Kind
B2
Abstract

According to the present invention, it becomes possible to perform a process for converting into an α-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance. In the production of an α-substituted-D-cysteine or a salt thereof, it becomes possible to perform a process for converting the compound represented by general formula (2) into a compound represented by general formula (3S) in one step by allowing an enzyme or the like to act on the compound represented by general formula (2).

Claims (65)

1. A method for producing an a-substituted cysteine represented by General Formula (1):

(wherein R 2 represents a C 1 -C 4 alkyl group) or a salt thereof, said method comprising the steps of:

allowing a base or an acid; or an enzyme having an activity to hydrolyze an ester group, a cell having an ability to produce the enzyme, a processed product of the cell, and/or a culture liquid containing the enzyme obtained by culturing the cell; to act on a compound represented by General Formula (2):

(wherein each R 1 independently represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and R 2 represents a C 1 -C 4 alkyl group), to obtain a compound represented by General Formula (3):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (2));

allowing a condensing agent or an acid halogenating agent to act on said compound represented by the General Formula (3), to obtain a compound represented by General Formula (4):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (2); X represents —OP(O)(OPh) 2 , —OP(O)(OEt) 2 , —OC(O)OR 3 , or a halogen atom; and R 3 represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted);

allowing an azidation agent to act on said compound represented by the General Formula (4), to obtain a compound represented by General Formula (5):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (2));

converting, by Curtius rearrangement reaction, said compound represented by the General Formula (5), to obtain a compound represented by General Formula (6):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (2)); and

subjecting said compound represented by the General Formula (6) to a process of converting the isocyanate group to an amino group, a process of hydrolyzing the ester group, and a process of removing the tert-butyl group by action of an acid.

2. The method for producing an α-substituted cysteine or a salt thereof according to claim 1 , wherein said enzyme is

(A) a protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16,or 18;

(B) a protein having an identity of not less than 35% to the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, or 18, and having an activity to hydrolyze said compound represented by the General Formula (2) for conversion into a compound represented by General Formula (3S):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (3)),

which is a compound represented by the General Formula (3) and having an (S)-configuration; or

(C) a protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, or 18 in which one or several amino acids are deleted, substituted, and/or added, and having an activity to hydrolyze said compound represented by the General Formula (2) for conversion into a compound represented by General Formula (3S), which is a compound represented by the General Formula (3) and having an (S)-configuration; and

said α-substituted cysteine represented by the General Formula (1) is an α-substituted cysteine represented by the following General Formula (1S) having an (S)-configuration:

(wherein R 2 has the same meaning as R 2 in the General Formula (1)).

3. A method for producing a compound represented by General Formula (3S) having optical purity of not less than 90.0% e.e:

(wherein R 1 represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and R 2 represents a C 1 -C 4 alkyl group), which is a compound represented by the General Formula (3):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (3S)) and having an (S)-configuration, said method comprising the step of:

allowing an enzyme having an activity to hydrolyze an ester group, a cell having an ability to produce the enzyme, a processed product of the cell, and/or a culture liquid containing the enzyme obtained by culturing the cell, to act on a compound represented by General Formula (2):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (3S)), wherein said enzyme is

(A) a protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, or 18;

(B) a protein having an identity of not less than 35% to the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, or 18, and having an activity to hydrolyze said compound represented by the General Formula (2) for conversion into said compound represented by the General Formula (3S) having the (S)-configuration; or

(C) a protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, or 18 in which one or several amino acids are deleted, substituted, and/or added, and having an activity to hydrolyze said compound represented by the General Formula (2) for conversion into said compound represented by the General Formula (3S) having the (S)-configuration.

4. The method for producing an α-substituted cysteine represented by General Formula (1):

(wherein R 2 represents a C 1 -C 4 alkyl group)

or a salt thereof according to claim 1 , wherein said subjecting step comprises the steps of:

allowing an acid to act on a compound represented by General Formula (6):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (6))

to construct a thiazolidinone ring, for conversion into a compound represented by General Formula (7-1):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (6));

allowing an acid or a base to act on said compound represented by the General Formula (7-1) to hydrolyze the ester group, to obtain a compound represented by General Formula (7-2):

(wherein R 2 has the same meaning as R 2 in the General Formula (7-1)); and

allowing an acid or a base to act on said compound represented by the General Formula (7-2) to open the thiazolidinone ring, to produce said a-substituted cysteine represented by the General Formula (1) or salt thereof.

5. A compound represented by General Formula (4-1):

(wherein R 1 and R 3 each independently represent a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and R 2 represents a C 1 -C 4 alkyl group.

6. A method for producing a compound represented by General Formula (2):

(wherein each R 1 independently represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and R 2 represents a C 1 -C 4 alkyl group),

said method comprising the step of:

allowing an alkylating agent to act on a compound represented by General Formula (9):

(wherein R 1 has the same meaning as R 1 in the General Formula (2)) in the presence of a base, or the steps of:

reacting tert-butyl mercaptan with formaldehyde to obtain tert-butylthiomethanol;

reacting tert-butylthiomethanol with a chlorinating agent in the presence of a base to obtain tert-butylthiochloromethane; and

allowing tert-butylthiochloromethane to act on a compound represented by General Formula (8):

(wherein R 1 has the same meaning as R 1 in the General Formula (2), and R 2 represents a C 1 -C 4 alkyl group) in the presence of a base, to obtain said compound represented by the General Formula (2).

7. A method for producing a compound represented by General Formula (4-1):

(wherein R 1 and R 3 each independently represent a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and R 2 represents a C 1 -C 4 alkyl group),

said method comprising the step of:

allowing a chloroformic ester to act on a compound represented by General Formula (3):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (4-1)).

8. A method for producing a compound represented by General Formula (5):

(wherein R 1 represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and

R 2 represents a C 1 -C 4 alkyl group), said method comprising the step of:

allowing a metal azide to act on a compound represented by General Formula (4-1):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (5), and R 3 represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted).

9. A method for producing a compound represented by General Formula (7-1):

(wherein R 1 represents a C 1 -C 10 alkyl group which is optionally substituted, a C 7 -C 20 aralkyl group which is optionally substituted, or a C 6 -C 12 aryl group which is optionally substituted, and

R 2 represents a C 1 -C 4 alkyl group),

said method comprising the step of:

allowing an acid to act on a compound represented by General Formula (6):

(wherein R 1 and R 2 have the same meanings as R 1 and R 2 in the General Formula (7-1)) to construct a thiazolidinone ring.

Assignments (3)
CHANGE OF ADDRESS Recorded Aug 21, 2025
From: API CORPORATION
To: API CORPORATION
Reel/Frame 072498/0511 →
MERGER Recorded Aug 21, 2025
From: API CORPORATION
To: UBE CORPORATION
Reel/Frame 072554/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ASUMA, YUUKI; UEHARA, HISATOSHI; MAEDA, TOMOKO; SAITO, YASUYO; MIYAKE, RYOMA; KAWABATA, HIROSHI
To: API CORPORATION
Reel/Frame 040857/0986 →
Priority Claims (1)
JP 2013-097172 · May 2, 2013 · national
Continuity (1)
Related Publication 20160083341A1 · Mar 24, 2016